Get the Stockscreener App
61.84
0.65%
0.40
Pre-market:
61.84
Kymera Therapeutics Inc stock is traded at $61.84, with a volume of 485.97K.
It is up +0.65% in the last 24 hours and up +9.26% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$61.44
Open:
$60.6
24h Volume:
485.97K
Relative Volume:
0.67
Market Cap:
$4.42B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-19.95
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+5.60%
1M Performance:
+9.26%
6M Performance:
+80.45%
1Y Performance:
+33.94%
1-Day Range:
$59.84
$62.24
1-Week Range:
$58.75
$62.24
52-Week Range:
$19.45
$63.96
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
61.84 | 4.39B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan
Is Kymera Therapeutics Inc. stock supported by innovation pipelineEntry Point & Free Verified High Yield Trade Plans - newser.com
Pattern recognition hints at Kymera Therapeutics Inc. upside2025 Top Decliners & Growth Focused Stock Reports - newser.com
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Acquires New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
34,797 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Moody Aldrich Partners LLC - MarketBeat
Is Kymera Therapeutics Inc. stock attractive for ETFsWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
Jennison Associates LLC Acquires 272,739 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat
How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener
KYMR insider trade: CEO option exercise and matching share sales - Stock Titan
How to read the order book for Kymera Therapeutics Inc.July 2025 Patterns & Safe Entry Momentum Tips - newser.com
Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance
How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance
Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - Fundação Cultural do Pará
How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewswire Inc.
What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará
Earnings Recap: Why Kymera Therapeutics Inc. stock could outperform in 2025Trend Reversal & Free Expert Approved Momentum Trade Ideas - Fundação Cultural do Pará
Why Kymera Therapeutics Inc. stock could outperform in 2025July 2025 Big Picture & Real-Time Stock Entry Alerts - fcp.pa.gov.br
Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis - TipRanks
Kymera’s IRF5 degrader shows promise in preclinical lupus, RA studies - Investing.com
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - Investing News Network
Kymera (NASDAQ: KYMR) shows KT-579 IRF5 degrader activity in lupus, RA at ACR - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kymera Therapeutics (KYMR) Awaits Key Phase 1b Data Release - GuruFocus
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout (KYMR:NASDAQ) - Seeking Alpha
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):